Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !
¡Desconecta con la aplicación Player FM !
atai life sciences reveals positive clinical trial results and discusses FDA ruling on MDMA
MP3•Episodio en casa
Manage episode 434163738 series 2891889
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
atai Life Sciences co-founder and co-CEO Dr Srinivas Rao takes Proactive's Stephen Gunnion through the positive results from the Phase 1b trial for VLS-01, emphasizing its excellent tolerability and potential as a best-in-class treatment option. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. VLS-01 is being developed for treatment-resistant depression, a condition that impacts the lives of an estimated 100 million people globally. Srinivas emphasizes the potential of VLS-01 as a best-in-class treatment option, with excellent tolerability, patient-friendly administration and a short 2-hour in-clinic treatment time. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. Rao noted that the next steps include advancing the 120mg dose into a robust Phase 2 trial for treatment-resistant depression, with results expected by the end of next year. He also addressed recent FDA decisions regarding MDMA and how atai's approach in trial design avoids similar pitfalls. Beyond VLS-01, Rao highlighted that the company is progressing its clinical development plans for EMP-01, which is oral R-MDMA, with a Phase 2 trial for social anxiety disorder set to initiate by the end of the year. Don't forget to like this video, subscribe to our channel, and turn on notifications to stay updated with our latest content. #AtaiLifeSciences #ClinicalTrials #VLS01 #MentalHealth #PharmaceuticalResearch #DepressionTreatment #Phase2Trial #FDA #Biotech #DrugDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodios
MP3•Episodio en casa
Manage episode 434163738 series 2891889
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
atai Life Sciences co-founder and co-CEO Dr Srinivas Rao takes Proactive's Stephen Gunnion through the positive results from the Phase 1b trial for VLS-01, emphasizing its excellent tolerability and potential as a best-in-class treatment option. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. VLS-01 is being developed for treatment-resistant depression, a condition that impacts the lives of an estimated 100 million people globally. Srinivas emphasizes the potential of VLS-01 as a best-in-class treatment option, with excellent tolerability, patient-friendly administration and a short 2-hour in-clinic treatment time. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. Rao noted that the next steps include advancing the 120mg dose into a robust Phase 2 trial for treatment-resistant depression, with results expected by the end of next year. He also addressed recent FDA decisions regarding MDMA and how atai's approach in trial design avoids similar pitfalls. Beyond VLS-01, Rao highlighted that the company is progressing its clinical development plans for EMP-01, which is oral R-MDMA, with a Phase 2 trial for social anxiety disorder set to initiate by the end of the year. Don't forget to like this video, subscribe to our channel, and turn on notifications to stay updated with our latest content. #AtaiLifeSciences #ClinicalTrials #VLS01 #MentalHealth #PharmaceuticalResearch #DepressionTreatment #Phase2Trial #FDA #Biotech #DrugDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodios
Tous les épisodes
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.